Progress and perspectives in chemoprevention of head and neck cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 3, 2003, Pages 339-355

  Wirth, Lori J ^a   Haddad, Robert I ^a   Posner, Marshall R ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Chemoprevention; Field cancerization; Head and neck cancer; Oral leukoplakia; Second primary tumor

Indexed keywords

ACETYLCYSTEINE; ALPHA DIFLUOROMETHYLARGININE; ALPHA INTERFERON; ALPHA TOCOPHEROL; BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; ETRETINATE; FENRETINIDE; INTERLEUKIN 6; INTERLEUKIN 8; ISOTRETINOIN; KETOROLAC; MITOGEN ACTIVATED PROTEIN KINASE; NEW DRUG; ONYX 015; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN P53; RETINOIC ACID RECEPTOR BETA; RETINOID X RECEPTOR; RETINOL PALMITATE; ROFECOXIB; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; UNINDEXED DRUG;

CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; HEAD AND NECK CANCER; HUMAN; NIGHT BLINDNESS; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SQUAMOUS CELL CARCINOMA; VALIDATION PROCESS;

EID: 0038207017     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.3.339     Document Type: Review

References (202)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 53(1), 5-26 (2003).
2. Sankaranarayanan R, Masuyer E, Swaminathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and prognosis. Anticancer Res. 18(6B), 4779-4786 (1998).
3. American Cancer Society, Surveillance Research. Cancer facts and figures. American Cancer Society, GA, USA, 1-41 (2001).
4. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90(18), 1371-1388 (1998).
5. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 281(23), 2189-2197 (1999).
6. Veronesi U, De Palo G, Marubini E et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl Cancer Inst. 91(21), 1847-1856 (1999).
7. Vogel VG. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin. Cancer Res. 7(12 Suppl.), 4413s-4418s (2001).
8. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342(26), 1946-1952 (2000).
9. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary β-carotene materially reduce human cancer rates? Nature 290(5803), 201-208 (1981).
10. National Research Council. Diet, nutrition and cancer. National Academy Press, WA, USA (1982).
11. Greenwald P. NCI cancer prevention and control research. Prev. Med. 22(5), 642-660 (1993).
12. Lippman SM, Benner SE, Hong WK. Retinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis. Cancer Res. 54(7 Suppl.), 2025s-2028s (1994).
13. The α-Tocopherol, β-Carotene Cancer Prevention Study Group.The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330 (15), 1029-1035 (1994).
14. Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334(18), 1150-1155 (1996).
15. Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334(18 , 1145-1149 (1996).
16. Lippman SM, Lee JJ, Karp DD et al. Randomized Phase III Intergroup trial of isotretinoin to prevent second primary tumors in Stage I non-small-cell lung cancer. J. Natl Cancer Inst. 93(8), 605-618 (2001).
17. Omenn GS, Goodman GE, Thornquist MD et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J. Natl Cancer Inst. 88(21), 1550-1559 (1996).
18. Hong WK, Endicott J, Itri LM et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med. 315(24), 1501-1505 (1986).
19. Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 323(12), 795-801 (1990).
20. Slaughter DL, Southwick HW, Smejkal W. 'Field cancerization' in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 6, 963 (1953).
21. Califano J, van der Riet P, Westra W et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res. 56(11), 2488-2492 (1996).
22. Bedi GC, Westra WH, Gabrielson E, Koch W, Sidransky D. Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res. 56(11), 2484-2487 (1996).
23. Scholes AG, Woolgar JA, Boyle MA et al. Synchronous oral carcinomas: independent or common clonal origin? Cancer Res. 58(9), 2003-2006 (1998).
24. Tabor MP, Brakenhoff RH, van Houten VM et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin. Cancer Res. 7(6), 1523-1532 (2001).
25. Brennan JA, Mao L, Hruban RH et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332(7), 429-435 (1995).
26. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63(8), 1727-1730 (2003).
27. Mao L, Lee JS, Fan YH et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nature Med. 2(6), 682-685 (1996).
28. Reed AL, Califano J, Cairns P et al. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56(16), 3630-3633 (1996).
29. Papadimitrakopoulou V, Izzo J, Lippman SM et al. Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 14(15), 1799-1803 (1997).
30. El-Naggar AK, Lai S, Clayman G et al. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am. J. Pathol. 151(6), 1767-1774 (1997).
31. Sanchez-Cespedes M, Esteller M, Wu L et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60(4), 892-895 (2000).
32. Rosas SL, Koch W, da Costa Carvalho MG et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61(3), 939-942 (2001).
33. Hasegawa M, Nelson HH, Peters E, Ringstrom E, Posner M, Kelsey KT. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21(27), 4231-4236 (2002).
34. Jares P, Fernandez PL, Campo E et al. PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res. 54(17), 4813-4817 (1994).
35. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 55(5), 975-978 (1995).
36. Izzo JG, Papadimitrakopoulou VA, Li XQ et al. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene 17(18), 2313-2322 (1998).
37. Okami K, Reed AL, Cairns P et al. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene 18(23), 3541-3545 (1999).
38. Papadimitrakopoulou VA, Izzo J, Mao L et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin. Cancer Res. 7(10), 3127-3134 (2001).
39. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res. 52(21), 5997-6000 (1992).
40. Boyle JO, Hakim J, Koch W et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 53(19), 4477-4480 (1993).
41. Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum. Pathol. 30(10), 1221-1225 (1999).
42. Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J. Oral Pathol. Med. 29(9), 413-425 (2000).
43. Shin DM, Charuruks N, Lippman SM et al. p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol. Biomarkers Prev. 10(6), 603-609 (2001).
44. Brennan JA, Boyle JO, Koch WM et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332(11), 712-717 (1995).
45. Koch WM, Brennan JA, Zahurak M et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J. Natl Cancer Inst. 88(21), 1580-1586 (1996).
46. Shin DM, Lee JS, Lippman SM et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J. Natl Cancer Inst 88(8), 519-529 (1996).
47. Geisler SA, Olshan AF, Weissler MC et al. p16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin. Cancer Res. 8(11), 3445-3453 (2002).
48. Califano J, Westra WH, Meininger G, Corio R, Koch WM, Sidransky D. Genetic progression and donal relationship of recurrent premalignant head and neck lesions. Clin. Cancer Res. 6(2), 347-352 (2000).
49. Kim ES, Hong WK, Khuri FR. Chemoprevention of aerodigestive tract cancers. Ann. Rev. Med. 53, 223-243 (2002).
50. Zhang L, Poh CF, Lam WL et al. Impact of localized treatment in reducing risk of progression of low- grade oral dysplasia: molecular evidence of incomplete resection. Oral Oncol. 37(6), 505-512 (2001).
51. Jiang WW, Fujii H, Shirai T, Mega H, Takagi M. Accumulative increase of loss of heterozygosity from leukoplakia to foci of early cancerization in leukoplakia of the oral cavity. Cancer 92(9), 2349-2356 (2001).
52. Papadimitrakopoulou VA, Liu DD, Mao L et al. Biologic correlates of a biochemoprevention trial in advanced upper aerodigestive tract premalignant lesions. Cancer Epidemiol. Biomarkers Prev. 11(12), 1605-1610 (2002).
53. Sudbo J, Kildal W, Risberg B, Koppang H, Danielsen HE, Reith A. DNA content as a prognostic marker in patients with oral leukoplakia. N. Engl. J. Med. 344(17), 1270-1278 (2001).
54. Sudbo J, Kildal W, Johannessen AC et al. Gross genomic aberrations in precancers: clinical implications of a long-term follow-up study in oral erythroplakias. J. Clin. Oncol. 20(2), 456-462 (2002).
55. Opitz OG, Harada H, Suliman Y et al. A mouse model of human oral-esophageal cancer. J. Clin. Invest. 110(6), 761-769 (2002).
56. Maser RS, DePinho RA. Connecting chromosomes, crisis and cancer. Science 297(5581), 565-569 (2002).
57. McCaul JA, Gordon KE, Clark LJ, Parkinson EK. Telomerase inhibition and the future management of head and neck cancer. Lancet Oncol. 3(5), 280-288 (2002).
58. Kannan S, Tahara H, Yokozaki H et al. Telomerase activity in premalignant and malignant lesions of human oral mucosa. Cancer Epidemiol. Biomarkers Prev. 6(6), 413-420 (1997).
59. Mao L, El-Naggar AK, Fan YH et al. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res. 56(24), 5600-5604 (1996).
60. Downey MG, Going JJ, Stuart RC, Keith WN. Expression of telomerase RNA in oesophageal and oral cancer. J. Oral Pathol. Med. 30(10), 577-581 (2001).
61. Xu XC, Ro JY, Lee JS, Shin DM, Hong WK, Lotan R. Differential expression of nuclear retinoid receptors in normal, premalignant and malignant head and neck tissues. Cancer Res. 54(13), 3580-3587 (1994).
62. Xu XC, Zile MH, Lippman SM et al. Antiretinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor-β expression. Cancer Res. 55(23), 5507-5511 (1995).
63. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit. Rev. Oncol. Hematol. 41(1), 41-55 (2002).
64. Todd R, Wong DT. Epidermal growth factor receptor (EGFR) biology and human oral cancer. Histol. Histopathol. 14(2), 491-500 (1999).
65. Ford AC, Grandis JR. Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25(1), 67-73 (2003).
66. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor-α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53(15), 3579-3584 (1993).
67. Shin DM, Ro JY, Hong WK, Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 54(12), 3153-3159 (1994).
68. Grandis JR, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78(6), 1284-1292 (1996).
69. Uhlman DL, Adams G, Knapp D, Aeppli DM, Niehans G. Immunohistochemical staining for markers of future neoplastic progression in the larynx. Cancer Res. 56(9), 2199-2205 (1996).
70. Grandis JR, Tweardy DJ, Melhern MF. Asynchronous modulation of transforming growth factor-α and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin. Cancer Res. 4(1), 13-20 (1998).
71. Grandis JR, Melhem MF, Gooding WE et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer Inst. 90(11), 824-832 (1998).
72. Dassonville O, Formento JL, Francoual M et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol. 11 (10), 1873-1878 (1993).
73. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 76(4), 655-663 (1990).
74. Chen Z, Malhotra PS, Thomas GR et al. Expression of pro-inflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin. Cancer Res. 5(6), 1369-1379 (1999).
75. Hong SH, Ondrey FG, Avis IM et al. Cyclooxygenase regulates human oropharyngeal carcinomas via the pro-inflammatory cytokine Il-6: a general role for inflammation? FASEB 14, 1499-1507 (2000).
76. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24(8), 792-799 (2002).
77. Moraitis D, Almahmeed T, Weksler B et al. Tobacco smoke induces cyclo-oxygenase-2 in epithelial cell lines derived from the human aerodigestive tract. AACR Abstracts 43, 349 (2002).
78. Wiese FW, Thompson PA, Kadlubar FF. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 22(1), 5-10 (2001).
79. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359(6398), 843-845 (1992).
80. Tsujii M, Kawano, S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93(5), 705-716 (1998).
81. Gallo O, Masini E, Bianchi B et al. Correlation between cyclooxygenase-2 pathways and tumor angiogenesis in head and neck cancer and its prognosistic Significance. Neoplasia 3, 53-66 (2000).
82. Seno H, Oshima M, Ishikawa TO et al. Cyclooxygenase-2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 62(2), 506-511 (2002).
83. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 62(3), 625-631 (2002).
84. Huang M, Stolina M, Sharma S et al. Non-small cell lung cancer cyclooxygenase2-dependent regulation of cytokine balance in lymphocytes and macrophages: upregulation of interleukin-10 and downregulation of interleukin-12 production. Cancer Res. 58(6), 1208-1216 (1998).
85. Salven P, Heikkila P, Anttonen A, Kajanti M, Joensuu H. Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod. Pathol. 10(11), 1128-1133 (1997).
86. Masferrer JL, Leahy KM, Koki AT et al. Anti-angiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60(5), 1306-1311 (2000).
87. Mineta H, Miura K, Ogino T et al. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br. J. Cancer 83(6), 775-781 (2000).
88. Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 18(10), 2046-2052 (2000).
89. The K, El-Naggar AK, Yoo E et al. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clin. Cancer Res. 6(7), 2821-2828 (2000).
90. Carlile J, Harada K, Baillie R et al. Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation. J. Oral Pathol. Med. 30(8), 449-457 (2001).
91. Chan G, Boyle JO, Yang EK et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res. 59(5), 991-994 (1999).
92. Nathan CA, Leskov IL, Lin M et al. COX-2 expression in dysplasia of the head and neck: correlation with elF4E. Cancer 92(7), 1888-1895 (2001).
93. Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 48(11), 3282-3287 (1988).
94. Franceschi S, Talamini R, Barra S et al. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx and esophagus in northern Italy. Cancer Res. 50(20), 6502-6507 (1990).
95. Negri E, La Vecchia C, Franceschi S, Tavani A. Attributable risk for oral cancer in northern Italy. Cancer Epidemiol. Biomarkers Prev. 2(3), 189-193 (1993).
96. Mashberg A, Boffetta P, Winkelman R, Garfinkel L. Tobacco smoking, alcohol drinking and cancer of the oral cavity and oropharynx among US veterans. Cancer 72(4), 1369-1375 (1993).
97. US Department of Health and Human Services (DHHS) Environmental Protection Agency. Respiratory health effects of passive smoking: lung cancer and other disorders. In: Smoking and tobacco control. DHHS, USA, monograph 4 (1993).
98. Muscat JE, Wynder EL. Tobacco, alcohol, asbestos and occupational risk factors for laryngeal cancer. Cancer 69(9), 2244-2251 (1992).
99. Hildesheim A, Dosemeci M, Chan CC et al. Occupational exposure to wood, formaldehyde and solvents and risk of nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 10 (11), 1145-1153 (2001).
100. Spitz MR, Fueger JJ, Beddingfield NA et al. Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res. 49(16), 4626-4628 (1989).
101. Schantz SP, Spitz MR, Hsu TC. Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. J. Natl Cancer Inst. 82(22), 1773-1775 (1990).
102. Spitz MR, Fueger JJ, Halabi S, Schantz SP, Sample D, Hsu TC. Mutagen sensitivity in upper aerodigestive tract cancer: a case-control analysis. Cancer Epidemiol. Biomarkers Prev. 2(4), 329-333 (1993).
103. Spitz MR, Hoque A, Trizna Z et al. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J. Natl Cancer Inst. 86(22), 1681-1684 (1994).
104. Cloos J, Spitz MR, Schantz SP et al. Genetic susceptibility to head and neck squamous cell carcinoma. J. Natl Cancer Inst. 88(8), 530-535 (1996).
105. Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK. Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J. Natl Cancer Inst. 89(3), 199-211 (1997).
106. Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J. Natl Cancer Inst. 93(18), 1411-1418 (2001).
107. Ko Y, Abel J, Harth V et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res. 61(11), 4398-4404 (2001).
108. Amador AG, Righi PD, Radpour S et al. Polymorphisms of xenobiotic metabolizing genes in oropharyngeal carcinoma. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 93(4), 440-445 (2002).
109. Zeng J, Gong CH, Jan MG, Fun Z, Zhang LG, Li HY. Detection of Epstein-Barr virus IgA/EA antibody for diagnosis of nasopharyngeal carcinoma by immunoautoradiography. Int. J. Cancer 31(5), 599-601 (1983).
110. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333(11), 693-698 (1995).
111. Chien YC, Chen JY, Liu MY et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med. 345(26), 1877-1882 (2001).
112. Miller WE, Cheshire JL, Baldwin AS Jr, Raab-Traub N. The NPC derived C15 LMP1 protein confers enhanced activation of NF-κB and induction of the EGFR in epithelial cells. Oncogene 16(14), 1869-1877 (1998).
113. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92(9), 709-720 (2000).
114. Mork J, Lie AY, Glattre E et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 344(15), 1125-1131 (2001).
115. Ha PK, Pai SI, Westra WH et al. Real-time quantitative PCR demonstrates low prevalence of human papillomavirus Type 16 in premalignant and malignant lesions of the oral cavity. Clin. Cancer Res. 8(5), 1203-1209 (2002).
116. Ringstrom E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT. Human papillomavirus Type 16 and squamous cell carcinoma of die head and neck. Clin. Cancer Res. 8(10), 3187-3192 (2002).
117. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 36(7 Pt 2), 2699-2702 (1976).
118. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87(2), 159-170 (1996).
119. Lippman SM, Hong WK. Cancer prevention science and practice. Cancer Res. 62(18), 5119-5125 (2002).
120. O'Shaughnessy JA, Kelloff GJ, Gordon GB et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res. 8(2), 314-346 (2002).
121. Lippman SM, Hong WK. Cancer prevention by delay. Commentary re: O'Shaughnessy JA et al., treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res. 8(2), 305-313 (2002).
122. Warren S, Gates O. Multiple primary tumors: a survey of the literature and statistical study. Am. J. Cancer 51, 1358 (1932).
123. Khuri FR, Kim ES, Lee JJ et al. The impact of smoking status, disease stage and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol. Biomarkers Prev. 10(8), 823-829 (2001).
124. Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH. Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 24(2), 198-206 (2002).
125. Vikram B. Changing patterns of failure in head and neck cancer. Archives of Otolaryngol. 110, 564-565 (1984).
126. Day GL, Blot WJ. Second primary tumors in patients with oral cancer. Cancer 70(1), 14-19 (1992).
127. Jones AS, Morar P, Phillips DE, Field JK, Husband D, Helliwell TR. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 75(6), 1343-1353 (1995).
128. Leon X, Quer M, Diez S, Orus C, Lopez-Pousa A, Burgues J. Second neoplasm in patients with head and neck cancer. Head Neck 21(3), 204-210 (1999).
129. Cooper JS, Pajak TF, Rubin P et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int. J. Radiat. Oncol. Biol. Phys. 17(3), 449-456 (1989).
130. Schwartz LH, Ozsahin M, Zhang GN et al. Synchronous and metachronous head and neck carcinomas. Cancer 74(7), 1933-1938 (1994).
131. Haughey BH, Gates GA, Arfken CL, Harvey J. Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann. Oncol. Rhinol. Laryngol. 101(2 Pt 1), 105-112 (1992).
132. Di Martino E, Sellhaus B, Hausmann R, Minkenberg R, Lohmann M, Esthofen MW. Survival in second primary malignancies of patients with head and neck cancer. J. Laryngol. Otol. 116(10), 831-838 (2002).
133. Larson JT, Adams GL, Fattah HA. Survival statistics for multiple primaries in head and neck cancer. Otolaryngol. Head Neck Surg. 103(1), 14-24 (1990).
134. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg. Oral Med. Oral Pathol. 46(4), 518-539 (1978).
135. Silverman S Jr, Gorsky M. Proliferative verrucous leukoplakia: a follow-up study of 54 cases. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 84(2), 154-157 (1997).
136. Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surg. Oral Med. Oral Pathol. 61(4), 373-381 (1986).
137. Waldron CA, Shafer WG. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer 36(4), 1386-1392 (1975).
138. Mashberg A, Meyers H. Anatomical site and size of 222 early asymptomatic oral squamous cell carcinomas: a continuing prospective study of oral cancer. Cancer 37(5), 2149-2157 (1976).
139. Silverman SJ, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 53, 563-568 (1984).
140. Bouquot JE, Weiland LH, Kurland LT. Leukoplakia and carcinoma in situ synchronously associated with invasive oral/oropharyngeal carcinoma in Rochester, MN, USA, 1935-1984. Oral Surg. Oral Med. Oral Pathol. 65(2), 199-207 (1988).
141. Lee JJ, Hong WK, Hittelman WN et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin. Cancer Res. 6(5), 1702-1710 (2000).
142. Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer 36(3), 1021-1028 (1975).
143. Sudbo J, Sondresen JE, Reith A, Ristimaki A, Nesland JM, Byrne M. Identifying patients at high risk of oral cancer and potential treatment possibilities. Proc. Am. Soc. Clin. Oncol. USA (2002) (Abstract 939).
144. Saito T, Sugiura C, Hirai A et al. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. Int. J. Oral Maxillofac. Surg. 30(1), 49-53 (2001).
145. Rosin MP, Lam WL, Poh C et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res. 62(22), 6447-6450 (2002).
146. Day GL, Blot WJ, Shore RE et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J. Natl Cancer Inst. 86(2), 131-137 (1994).
147. Shiu MN, Chen TH, Chang SH, Hahn LJ. Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. Br. J. Cancer 82(11), 1871-1874 (2000).
148. Rosin MP, Cheng X, Poh C et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin. Cancer Res. 6(2), 357-362 (2000).
149. Partridge M, Pateromichelakis S, Phillips E, Emilion GG, A'Hern RP, Langdon JD. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res. 60(14), 3893-3898 (2000).
150. Zhang L, Epstein JB, Poh CF et al. Comparison of HPV infection, p53 mutation and allelic losses in post-transplant and non-posttransplant oral squamous cell carcinomas. J. Oral Pathol. Med. 31(3), 134-141 (2002).
151. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J. Clin. 52(4), 195-215 (2002).
152. Vedtofte P, Holmstrup P, Hjorting-Hansen E, Pindborg JJ. Surgical treatment of premalignant lesions of the oral mucosa. Int. J. Oral Maxillofac. Surg. 16(6), 656-664 (1987).
153. Lydiatt WM, Anderson PE, Bazzana T et al. Molecular support for field cancerization in the head and neck. Cancer 82(7), 1376-1380 (1998).
154. Thomson PJ. Field change and oral cancer: new evidence for widespread carcinogenesis? Int. J. Oral Maxillofac. Surg. 31(3), 262-266 (2002).
155. Lotan R. Retinoids and their receptors in modulation of differentiation, development and prevention of head and neck cancers. Anticancer Res. 16(4C), 2415-2419 (1996).
156. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21(7), 1271-1279 (2000).
157. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett. 40(1), 93-101 (1988).
158. Michaelsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N. Engl. J. Med. 348(4), 287-294 (2003).
159. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA 287(1), 47-54 (2002).
160. Lippman SM, Batsakis JG, Toth BB et al. Comparison of low-dose isotretinoin with β-carotene to prevent oral carcinogenesis. N. Engl. J. Med. 328(1), 15 (1993).
161. Stich HF, Rosin MP, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with β-carotene and with β-carotene plus vitamin A. Int. J. Cancer 42(2), 195-199 (1988).
162. Papadimitrakopoulou VA, Clayman GL, Shin DM et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch. Otolaryngol. Head Neck Surg. 125(10), 1083-1089 (1999).
163. Chiesa F, Tradati N, Marazza M et al. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J. Cell. Biochem. Suppl. 17F, 255-261 (1993).
164. Lodi G, Sardella A, Bez C, Demarosi F, Carrassi A. Systematic review of randomized trials for the treatment of oral leukoplakia. J. Dent. Educ. 66(8), 896-902 (2002).
165. Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Natl Cancer Inst. 86(2), 140-141 (1994).
166. Bolla M, Lefur R, Ton Van J et al. Prevention of second primary tumours with etretinate in squamous; cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur. J. Cancer 30A(6), 767-772 (1994).
167. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Co-operative Groups. J. Natl Cancer Inst. 92(12), 977-986 (2000).
168. Mayne ST, Cartmel B, Baum M et al. Randomized trial of supplemental β-carotene to prevent second head and neck cancer. Cancer Res. 61(4), 1457-1463 (2001).
169. Shin DM, Khuri FR, Murphy B et al. Combined interferon-α, 13-cis-retinoic acid and α-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant Phase II trial. J. Clin. Oncol. 19(12), 3010-3017 (2001).
170. Lippman SM, Shin DM, Lee JJ et al. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res. 55(1), 16-19 (1995).
171. Shin DM, Xu XC, Lippman SM et al. Accumulation of p53 protein and retinoic acid receptor-β in retinoid chemoprevention. Clin. Cancer Res. 3(6), 875-880 (1997).
172. Sun SY, Yue P, Kelloff GJ et al. Identification of retinamides that are more potent than N-(4-hydroxyphenyl) retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. Cancer Epidemiol. Biomarkers Prev. 10(6), 595-601 (2001).
173. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 21(3), 525-530 (2000).
174. Suh N, Lamph WW, Glasebrook AL et al. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene and a new rexinoid, LG 100268. Clin. Cancer Res. 8(10), 3270-3275 (2002).
175. Suh N, Glasebrook AL, Palkowitz AD et al. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. 61(23), 8412-8415 (2001).
176. Suchanek KM, May FJ, Robinson JA et al. Peroxisome proliferator-activated receptor-α in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol. Carcinog. 34(4), 165-171 (2002).
177. Ikawa H, Kameda H, Kamitani H et al. Effect of PPAR activators on cytokine-stimulated cyclooxygenase-2 expression in human colorectal carcinoma cells. Exp. Cell Res. 267(1), 73-80 (2001).
178. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83(3), 493-501 (1995).
179. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J. Biol. Chem. 276(52), 48997-49002 (2001).
180. Yan Z, Subbaramaiah K, Camilli T et al. Benzo[a]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. Evidence for the involvement of extracellular signal-regulated kinase and NF-κB. J. Biol. Chem. 275(7), 4949-4955 (2000).
181. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase-2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24(2), 96-102 (2003).
182. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Med. 8(3), 289-293 (2002).
183. Dannenberg AJ, Altorki NK, Boyle JO et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancer Oncol. 2, 544-551 (2001).
184. Meyskens FL Jr, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res. 5(5), 945-951 (1999).
185. Jacoby RF, Cole CE, Tutsch K et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas and selective toxicity against Apc mutant embryos. Cancer Res. 60(7), 1864-1870 (2000).
186. D'Ambrosio SM, Gibson-D'Ambrosio R, Milo GE, Casto B, Kelloff GJ, Steele VE. Differential response of normal, premalignant and malignant human oral epithelial cells to growth inhibition by chemopreventive agents. Anticancer Res. 20(4), 2273-2280 (2000).
187. Khafif A, Schantz SP, Chou TC, Edelstein D, Sacks PG. Quantitation of chemopreventive synergism between (-)epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 19(3), 419-424 (1998).
188. Lamy S, Gingras D, Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. 62(2), 381-385 (2002).
189. Li N, Chen X, Liao J et al. Inhibition of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 23(8), 1307-1313 (2002).
190. Cheng AL, Hsu CH, Lin JK et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21(4B), 2895-2900 (2001).
191. Rocco JW, Li D, Liggett WH Jr et al. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin. Cancer Res. 4(7), 1697-1704 (1998).
192. Nemunaitis J, Khuri F, Ganly I et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19(2), 289-298 (2001).
193. Nemunaitis J, O'Brien J. Head and neck cancer: gene therapy approaches. Part 1: adenoviral vectors. Exp. Opin. Biol. Ther. 2(2), 177-185 (2002).
194. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res. 5(7), 1715-1722 (1999).
195. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther. 9(12), 979-986 (2002).
196. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus Type 16 vaccine. N. Engl. J. Med. 347(21), 1645-1651 (2002).
197. Duraiswamy J, Sherritt M, Thomson S et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin's disease and nasopharyngeal carcinoma. Blood 101(8), 3150-3156 (2003).
198. Sankaranarayanan R, Mathew B, Varghese C et al. Chemoprevention of oral leukoplakia with vitamin A and β-carotene: an assessment. Oral Oncol. 33(4), 231-236 (1997).
199. Epstein JB, Gorsky M, Wong FL, Millner A. Topical bleomycin for the treatment of dysplastic oral leukoplakia. Cancer 83(4), 629-634 (1998).
200. Epstein JB, Gorsky M. Topical application of vitamin A to oral leukoplakia: a clinical case series. Cancer 86(6), 921-927 (1999).
201. Li N, Sun Z, Han C, Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proc. Soc. Exp. Biol. Med. 220(4), 218-224 (1999).
202. Pinto H, Li Y, Kardinal C, Adams G, Pandya K. Phase III trial of low-dose 13-cis-retinoic acid for prevention of second primary cancers in Stage I-II head and neck cancer - an Eastern Co-operative Group Study. Proc. Am. Soc. Clin. Oncol. (2001) (Abstract 886).